Sunday, March 24, 2013

House Republicans Eye Off-Label Promotion, Antibiotics As FDA Reform Priorities

Off-Label Debate

Republicans on the House Energy and Commerce Committee's health panel will seek ways to give providers and drug manufacturers more clarity regarding off-label uses of drugs as part of an FDA policy agenda that also includes clarifying mobile medical application regulation, incentivizing antibiotic development and creating an FDA board of directors akin to CMS' Medicare Payment Advisory Commission.
Source found here

No comments: